Ebola virus vaccine - Profectus Biosciences
Alternative Names: Ebola Zaire Vaccine - Profectus Biosciences; Monovalent vesicular stomatitis virus vectored Ebola virus vaccine - Profectus Biosciences; rVSVN4CT1 EBOVGP1; VesiculoVax™ Zaire-Ebola virus - Profectus Biosciences; VesiculoVax™-vectored Ebola virus vaccine - Profectus BiosciencesLatest Information Update: 25 Nov 2021
At a glance
- Originator Profectus Biosciences
- Class Antivirals; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ebola virus infections
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for phase-I development in Ebola-virus-infections(Prevention) in USA (IM)
- 19 Jan 2016 Phase-I clinical trials in Ebola virus infections (Prevention) in USA (IM)
- 23 Sep 2011 Preclinical trials in Ebola virus infections in USA (IM)